Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia
Warm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder mediated by autoantibodies. With an increasing understanding of the immunopathogenesis of wAIHA, significant progress has been made in the development of drugs targeting different components of the immune system. Consequently, these...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2025-02-01
|
| Series: | Xiehe Yixue Zazhi |
| Subjects: | |
| Online Access: | https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726180011278336 |
|---|---|
| author | WANG Qi CHEN Miao |
| author_facet | WANG Qi CHEN Miao |
| author_sort | WANG Qi |
| collection | DOAJ |
| description | Warm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder mediated by autoantibodies. With an increasing understanding of the immunopathogenesis of wAIHA, significant progress has been made in the development of drugs targeting different components of the immune system. Consequently, these emerging drugs provide more options for the treatment of patients with wAIHA. Anti-B-cell targeted therapies, represented by novel CD20 monoclonal antibodies, Bruton tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinases(PI3K) inhibitors, and B-cell activating factor of the TNF family (BAFF) inhibitors, have shown remarkable efficacy. Additionally, anti-plasma cell targeted therapies, exemplified by proteasome inhibitors and CD38 monoclonal antibodies, have also demonstrated significant outcomes. Furthermore, advances have been achieved in complement inhibitors, neonatal Fc receptor (FcRn) monoclonal antibodies, spleen tyrosine kinase (SYK) inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. This article reviews the recent advances in immunotargeted therapy for wAIHA, aiming to provide a reference for clinical practice. |
| format | Article |
| id | doaj-art-a03e1ffd08ea40b98bbb69044974d9e7 |
| institution | DOAJ |
| issn | 1674-9081 |
| language | zho |
| publishDate | 2025-02-01 |
| publisher | Editorial Office of Medical Journal of Peking Union Medical College Hospital |
| record_format | Article |
| series | Xiehe Yixue Zazhi |
| spelling | doaj-art-a03e1ffd08ea40b98bbb69044974d9e72025-08-20T03:10:16ZzhoEditorial Office of Medical Journal of Peking Union Medical College HospitalXiehe Yixue Zazhi1674-90812025-02-0116242343010.12290/xhyxzz.2024-0668Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic AnemiaWANG Qi0CHEN Miao1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, ChinaWarm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder mediated by autoantibodies. With an increasing understanding of the immunopathogenesis of wAIHA, significant progress has been made in the development of drugs targeting different components of the immune system. Consequently, these emerging drugs provide more options for the treatment of patients with wAIHA. Anti-B-cell targeted therapies, represented by novel CD20 monoclonal antibodies, Bruton tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinases(PI3K) inhibitors, and B-cell activating factor of the TNF family (BAFF) inhibitors, have shown remarkable efficacy. Additionally, anti-plasma cell targeted therapies, exemplified by proteasome inhibitors and CD38 monoclonal antibodies, have also demonstrated significant outcomes. Furthermore, advances have been achieved in complement inhibitors, neonatal Fc receptor (FcRn) monoclonal antibodies, spleen tyrosine kinase (SYK) inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. This article reviews the recent advances in immunotargeted therapy for wAIHA, aiming to provide a reference for clinical practice.https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0668warm autoantibody typeautoimmune hemolytic anemiaimmunotherapytargeted therapy |
| spellingShingle | WANG Qi CHEN Miao Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia Xiehe Yixue Zazhi warm autoantibody type autoimmune hemolytic anemia immunotherapy targeted therapy |
| title | Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia |
| title_full | Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia |
| title_fullStr | Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia |
| title_full_unstemmed | Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia |
| title_short | Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia |
| title_sort | advances in immunotargeted therapy for warm autoimmune hemolytic anemia |
| topic | warm autoantibody type autoimmune hemolytic anemia immunotherapy targeted therapy |
| url | https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0668 |
| work_keys_str_mv | AT wangqi advancesinimmunotargetedtherapyforwarmautoimmunehemolyticanemia AT chenmiao advancesinimmunotargetedtherapyforwarmautoimmunehemolyticanemia |